Navigation Links
Ventria Expands Team and Hires Kansan as Director of Bioprocessing Operations
Date:1/9/2008

JUNCTION CITY, Kan., Jan. 9 /PRNewswire/ -- Ventria Bioscience announced today that Angus Connell would be joining the company as Director of Bioprocessing Operations for the company's Junction City facility.

Connell, a Kansas native, has extensive experience in operations, engineering design and process development leadership with Koch Industries and Coffeyville Resources. At Koch Industries, he held positions including Manager of Process Engineering and Director of Engineering and Research. He was most recently the Operations Manager for Coffeyville Resources. Angus received his Bachelor of Science degree in Chemical Engineering from the University of Tulsa.

"Angus brings a wealth of process engineering, operations management, and plant expansion capabilities to our team in Junction City," said Greg Unruh, Vice President and General Manager, Ventria Bioscience. "His experience is vital as we continue with the expansion of our facility. We are continually searching for talented employees with engineering, biology and agronomy experience to fill open positions in our Kansas operations. Many of the candidates we have hired in the last year have been trained by Kansas State University, University of Kansas, McPherson College and other Kansas-based educational institutions. Many are Kansas natives, like Angus, who are looking for the opportunity to become part of the bioscience industry in their home state of Kansas," he said.

"I am quite happy for the opportunity to remain in Kansas, at the same time I get to work in a cutting edge industry where I can continue to learn. My other opportunities would have required me to leave Kansas in order to advance my career," said Connell.

About Ventria

A recent child health study showed that Ventria's Lactiva and Lysomin helped reduce the duration of diarrhea in children by 30 percent when added to rehydration solutions. Childhood diarrhea is the second leading killer of children, claiming 2 million lives annually according to the World Health Organization.

For more information, see our website: http://www.ventria.com

Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.


'/>"/>
SOURCE Ventria Bioscience
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Science Teachers Tour Ventrias Bioprocessing Facility
2. Symmetry Medical Expands Board of Directors
3. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
4. Observant LLC Expands Senior Management Team
5. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
6. HealthTrust Expands Contract With Instrumentation Laboratory for Critical Care Portfolio to Include Consorta
7. CSL Behring Expands Into Middle East Market with Haemate(R) P
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
10. Siemens Expands the SOMATOM Definition(TM) Line With Worlds First Adaptive CT Scanner
11. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):